FDA grants orphan drug designation to silmitasertib for biliary tract cancer
Click Here to Manage Email Alerts
The FDA granted orphan drug designation to silmitasertib for treatment of biliary tract cancer.
Silmitasertib (Senhwa Biosciences) is a highly selective inhibitor of casein kinase 2 (CK2).
“We are pleased to receive [orphan drug designation] for silmitasertib for the treatment of biliary tract cancer, a rare, malignant disease for which there are no effective therapies,” Mei-Hui Kuo, acting CEO of Senhwa Biosciences, said in a company-issued press release. “[Orphan drug designation] represents an important regulatory milestone that has the potential to expedite the clinical development of silmitasertib.”
Standard first-line treatment for biliary tract cancer consists of chemotherapy with gemcitabine with cisplatin. There are no standard regimens for patients with locally advanced or metastatic disease after first-line chemotherapy fails.
Preclinical studies showed CK2 inhibition with silmitasertib prevents DNA repair, induces apoptosis, and enhances the antitumor activity of gemcitabine and cisplatin, according to the release.
Click Here to Manage Email Alerts